Amy Abernethy, M.D., Ph.D., is cofounder of Highlander Health, an organization focused on advancing evidence generation for the new era of medical innovation. As an oncologist, serial entrepreneur, and standard setter, Dr. Abernethy is a champion for speeding the pace at which safe and effective treatments reach patients, and for progressive and responsible use of our healthcare system’s data.
She is the former principal deputy commissioner of the U.S. Food and Drug Administration. While there, Dr. Abernethy led initiatives in advancing clinical evidence generation and personalized healthcare and also served as the agency's acting chief information officer.
More recently, Dr. Abernethy served as chief medical officer and president of product development at Verily, Alphabet’s precision health business, leading the company’s development and delivery of solutions that connect clinical research and care. Earlier roles include that of Flatiron Health’s first chief medical officer and chief scientific officer, as well as: professor of medicine at Duke University School of Medicine; director of the Center for Learning Health Care at the Duke Clinical Research Institute; and, director of the Duke Cancer Care Research Program at the Duke Cancer Institute. An avid learner and teacher, and a hematologist/oncologist and palliative medicine physician, Dr. Abernethy has authored over 500 publications.
Elected to the Board of Trustees of Duke University in 2024, Dr. Abernethy serves on the Graduate and Professional Education and Research Committee.
July 2024